0001298709-23-000023.txt : 20231212
0001298709-23-000023.hdr.sgml : 20231212
20231212171731
ACCESSION NUMBER: 0001298709-23-000023
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231211
FILED AS OF DATE: 20231212
DATE AS OF CHANGE: 20231212
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Krishnan Krish S
CENTRAL INDEX KEY: 0001298709
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38210
FILM NUMBER: 231482083
MAIL ADDRESS:
STREET 1: 2100 WHARTON STREET
STREET 2: SUITE 701
CITY: PITTSBURGH
STATE: PA
ZIP: 15203
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Krystal Biotech, Inc.
CENTRAL INDEX KEY: 0001711279
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 821080209
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2100 WHARTON STREET
STREET 2: SUITE 701
CITY: PITTSBURGH
STATE: PA
ZIP: 15203
BUSINESS PHONE: (412) 586-5830
MAIL ADDRESS:
STREET 1: 2100 WHARTON STREET
STREET 2: SUITE 701
CITY: PITTSBURGH
STATE: PA
ZIP: 15203
4
1
wk-form4_1702419441.xml
FORM 4
X0508
4
2023-12-11
0
0001711279
Krystal Biotech, Inc.
KRYS
0001298709
Krishnan Krish S
C/O KRYSTAL BIOTECH, INC.
2100 WHARTON STREET, SUITE 701
PITTSBURGH
PA
15203
1
1
1
0
President and CEO
1
Common Stock
2023-12-11
4
S
0
4400
104.4146
D
1654938
D
Common Stock
2023-12-11
4
S
0
6263
105.5039
D
1648675
D
Common Stock
2023-12-11
4
S
0
14237
106.1085
D
1634438
D
Common Stock
2023-12-11
4
S
0
100
107.66
D
1634338
D
Common Stock
2023-12-11
4
S
0
2854
104.2639
D
1596352
I
By Spouse
Common Stock
2023-12-11
4
S
0
4541
105.0621
D
1591811
I
By Spouse
Common Stock
2023-12-11
4
S
0
17505
106.0406
D
1574306
I
By Spouse
Common Stock
2023-12-11
4
S
0
100
107.66
D
1574206
I
By Spouse
Common Stock
90000
I
By Krishnan Spousal Trust
Common Stock
50000
I
By Krishnan Family Trust
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on September 11, 2023 and will terminate on September 11, 2024 and contemplates sales of 25,000 shares per quarter with a limit price of $100.00 per share.
The transaction was executed in multiple trades ranging from $103.9000 to $104.8800. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
The transaction was executed in multiple trades ranging from $104.9000 to $105.8900. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
The transaction was executed in multiple trades ranging from $105.9000 to $106.5500. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Suma M. Krishnan. The Rule 10b5-1 trading plan started on September 11, 2023 and will terminate on September 11, 2024 and contemplates sales of 25,000 shares per quarter with a limit price of $100.00 per share.
These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Suma M. Krishnan.
The transaction was executed in multiple trades ranging from $103.5600 to $104.5500. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
Directly beneficially owned by Suma M. Krishnan, the spouse of the Reporting Person.
The transaction was executed in multiple trades ranging from $104.5600 to $105.5400. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
The transaction was executed in multiple trades ranging from $105.5600 to $106.5500. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
Directly beneficially owned by the Krishnan Family Trust. The Reporting Person and his spouse are each joint beneficial owners of the trust with joint voting and investment control.
/s/ Krish S. Krishnan
2023-12-12